Skip to Main Content
Close Menu
About Us
Pipeline
Partnering
News
Resources
Careers
Contact Us
News Releases
View All Resources
Kallyope Presents New Data on Novel TRPM8 Channel Blocker Elismetrep for the Acute Treatment for Migraine at the American Headache Society 68th Annual Scientific Meeting
June 4th, 2026
Kallyope’s Phase 2b Study of Elismetrep, A Novel Approach for Treating Migraine, Presented at the American Academy of Neurology Annual Meeting
April 22nd, 2026
Kallyope to Present Phase 2b Study Results for Elismetrep for the Acute Treatment of Migraine at the 2026 American Academy of Neurology Annual Meeting
March 5th, 2026
Go to top